Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.48 |
| ▸ | CCNK | O75909 | 2/20 | 0.43 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 3/20 | 0.41 |
| ▸ | TTBK1 | Q5TCY1 | 4/20 | 0.40 |
| ▸ | TTBK2 | Q6IQ55 | 4/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.40 |
| ▸ | PRKCI | P41743 | 2/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1327890 | 0.86 | BRD4 (0.47) | BRD4METAAK1 | |
| SCHEMBL1329848 | 0.84 | AAK1 (0.52) | BRD4CCNKCDK12TTBK1TTBK2 | |
| SCHEMBL1330150 | 0.83 | BRD4 (0.49) | BRD4CCNKCDK12AAK1PRKCI | |
| SCHEMBL1327827 | 0.83 | BRD4 (0.48) | BRD4CCNKCDK12TTBK1TTBK2 | |
| SCHEMBL858643 | 0.83 | TTBK1 (0.46) | BRD4CCNKCDK12METTTBK1 | |
| SCHEMBL1329521 | 0.82 | CCNK (0.44) | BRD4CCNKCDK12METTTBK1 | |
| SCHEMBL1328118 | 0.78 | GRM5 (0.51) | BRD4CCNKCDK12TTBK1TTBK2 | |
| SCHEMBL10124939 | 0.77 | BRD4 (0.61) | BRD4CCNKCDK12PRKCIROCK1 | |
| SCHEMBL1328557 | 0.77 | BRD4 (0.45) | BRD4CCNKCDK12TTBK1TTBK2 | |
| SCHEMBL12346480 | 0.75 | BRD4 (0.61) | BRD4CCNKCDK12ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110282056-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-11-17 | — | — | US | claimed |
| EP-2231282-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | Merck Patent GmbH (DE) | 2010-09-29 | — | — | EP | claimed |
| WO-2009094123-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2009-07-30 | — | — | WO | claimed |
| US-20110282056-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110282056-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MAP3K19, MAP3K20, MAP3K1 | BRD4 1599/4885CCNK 313/4885CDK12 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.